Fahd Quddus
Hematology & Oncology · Greenville, SCNPI 1952530677
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,121 of the $4,019 with a category attached, or 77.7%. It is spread thinly across 33 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,286 and has fallen 57.5% since, to $547 in 2025. That places this record below the midpoint for hematology & oncology clinicians in SC, where the typical reported total is $4,020.
Across 91 payments — averaging $44.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$909
- Johnson & Johnson$431
- Mallinckrodt Hospital Products Inc.$257
- AstraZeneca$227
- GSK$216
- Adaptive Biotechnologies Corporation$177
- plus $2K from 27 others
Across 62 payments — averaging $7529.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$267K
- Amgen$74K
- Morphosys AG$43K
- E.r. Squibb & Sons, L.L.C.$36K
- Otsuka Pharmaceutical Co., Ltd.$34K
- Incyte Corporation$9K
- plus $5K from 1 others
What the payments were for
- Food & beverage$3,12178%
- Education$1163%
- Other$78119%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 14 | $909 |
| Johnson & Johnson | 8 | $431 |
| Mallinckrodt Hospital Products Inc. | 2 | $257 |
| AstraZeneca | 2 | $227 |
| GSK | 2 | $216 |
| Adaptive Biotechnologies Corporation | 3 | $177 |
| Sanofi | 3 | $162 |
| Amgen | 5 | $148 |
| E.r. Squibb & Sons, L.L.C. | 5 | $147 |
| Gilead(2 entities) | 4 | $144 |
| Incyte Corporation | 3 | $124 |
| Acrotech Biopharma Inc. | 1 | $123 |
| AbbVie | 1 | $121 |
| Kyowa Kirin, Inc. | 2 | $118 |
| Mallinckrodt Enterprises LLC | 1 | $112 |
| Servier Pharmaceuticals LLC | 1 | $101 |
| Pfizer | 8 | $80 |
| Ipsen Biopharmaceuticals, Inc | 4 | $67 |
| Taiho Oncology, Inc. | 3 | $52 |
| Bristol Myers Squibb | 3 | $43 |
| Genentech USA, Inc. | 3 | $40 |
| Janssen Scientific Affairs, LLC | 1 | $34 |
| Bayer | 2 | $33 |
| Eisai Inc. | 1 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Merck | 1 | $17 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $17 |
| Secura Bio, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $13 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
| Karyopharm Therapeutics Inc. | 1 | $12 |
| EMD Serono, Inc. | 1 | $11 |
| Clovis Oncology, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,019 in reported general payments places this provider in the 45th percentile of 166 hematology & oncology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 56 | $1,270,649 |
| RevlimidLenalidomide | 18 | $330,000 |
| Lenalidomide | 19 | $230,388 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 17 | $141,238 |
| OxbrytaVoxelotor | 11 | $134,564 |
| RetevmoSelpercatinib | 12 | $132,603 |
| CalquenceAcalabrutinib Maleate | 12 | $92,390 |
| EliquisApixaban | 131 | $82,773 |
| XareltoRivaroxaban | 57 | $62,620 |
| Imatinib Mesylate | 12 | $1,212 |
| Valganciclovir Hcl | 12 | $1,113 |
| Acyclovir | 74 | $614 |
| Morphine Sulfate ErMorphine Sulfate | 14 | $567 |
| Anastrozole | 18 | $541 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 15 | $533 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $147 | $1,270,64956 claims |
| Bristol Myers SquibbRevlimid | $43 | $330,00018 claims |
| AstraZenecaCalquence | $227 | $92,39012 claims |
| PfizerEliquis | $80 | $82,773131 claims |
| Johnson & JohnsonXarelto | $431 | $62,62057 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 166 hematology & oncology providers in South Carolina.
Other hematology & oncology in Greenville
- Suzanne FanningGreenville$927K
- Stephen DyarGreenville$413K
- Bhumika PatelGreenville$225K
- Joe StephensonGreenville$57K
- Elizabeth CullGreenville$16K
- Kevin KoehlerGreenville$10K
- Paige GanemGreenville$9K
- Vikas DemblaSpartanburg$568K
- Kashyap PatelRock Hill$379K
- Tondre BuckSpartanburg$366K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.